Page last updated: 2024-11-05

thalidomide and Erdheim-Chester Disease

thalidomide has been researched along with Erdheim-Chester Disease in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Erdheim-Chester Disease: A rare form of non-Langerhans-cell histiocytosis (HISTIOCYTOSIS, NON-LANGERHANS-CELL) with onset in middle age. The systemic disease is characterized by infiltration of lipid-laden macrophages, multinucleated giant cells, an inflammatory infiltrate of lymphocytes and histiocytes in the bone marrow, and a generalized sclerosis of the long bones.

Research Excerpts

ExcerptRelevanceReference
"We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease."8.88[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012)
"Treatment with 2-chlorodeoxyadenosine-based regimen provided partial remission of Erdheim-Chester disease lesions in the brain, while treatment with lenalidomide resulted in complete remission of these lesions."7.77[Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide]. ( Adam, Z; Cervinek, L; Hájek, R; Hermanová, M; Koukalová, R; Král, Z; Krejcí, M; Kren, L; Mayer, J; Mechl, M; Moulis, M; Pour, L; Prásek, J; Rehák, Z; Sprláková, A; Szturz, P; Zahradová, L, 2011)
"We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease."4.88[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012)
"Treatment with 2-chlorodeoxyadenosine-based regimen provided partial remission of Erdheim-Chester disease lesions in the brain, while treatment with lenalidomide resulted in complete remission of these lesions."3.77[Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide]. ( Adam, Z; Cervinek, L; Hájek, R; Hermanová, M; Koukalová, R; Král, Z; Krejcí, M; Kren, L; Mayer, J; Mechl, M; Moulis, M; Pour, L; Prásek, J; Rehák, Z; Sprláková, A; Szturz, P; Zahradová, L, 2011)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adam, Z2
Sprláková, A1
Rehák, Z2
Koukalová, R2
Szturz, P2
Krejcí, M2
Pour, L2
Zahradová, L2
Cervinek, L1
Kren, L1
Moulis, M1
Hermanová, M1
Mechl, M1
Prásek, J1
Hájek, R2
Král, Z2
Mayer, J2
Nebeský, T1

Reviews

1 review available for thalidomide and Erdheim-Chester Disease

ArticleYear
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
    Vnitrni lekarstvi, 2012, Volume: 58, Issue:11

    Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le

2012

Other Studies

1 other study available for thalidomide and Erdheim-Chester Disease

ArticleYear
[Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2011, Volume: 24, Issue:5

    Topics: Adult; Bone Marrow; Brain; Cladribine; Erdheim-Chester Disease; Humans; Lenalidomide; Magnetic Reson

2011